Ignyta Inc
11095 Flintkote Avenue
Suite D
San Diego
California
92121
United States
Website: http://www.ignyta.com/
Email: info@ignyta.com
163 articles about Ignyta Inc
-
Ignyta Announces Oral Plenary Presentation And Poster Presentations At The 2016 AACR Annual Meeting
4/8/2016
-
Ignyta Reports Granting Of Inducement Award
3/16/2016
-
Ignyta Announces 2015 Full Year Company Highlights And Financial Results
3/15/2016
-
Ignyta Announces Selection Of Recommended Phase 2 Dose And Initiation Of Phase 1b Basket Trial Of RXDX-105
3/10/2016
-
Ignyta To Report 2015 Company Highlights And Financial Results And Host Conference Call On March 14, 2016
3/9/2016
-
SoCal's Ignyta Ceases Development of Certain Drug Programs to Focus on Priority Pipeline
2/24/2016
-
Ignyta Reports Granting Of Inducement Awards
2/16/2016
-
Ignyta Announces Initiation Of Phase 1/1b Clinical Trial Of Taladegib In Combination With Paclitaxel By Cancer Research UK
2/4/2016
-
Ignyta To Present At Leerink Partners 5th Annual Global Healthcare Conference
2/2/2016
-
Ignyta Reports Granting Of Inducement Awards
1/18/2016
-
Ignyta Unveils "5X5" Goal And Announces 2016 Strategic Priorities
1/11/2016
-
Ignyta To Present At 34th Annual J.P. Morgan Healthcare Conference
1/7/2016
-
Ignyta Reports Granting Of Inducement Awards
12/16/2015
-
Ignyta Announces Accreditation Of Its Diagnostic Laboratory By College of American Pathologists
12/14/2015
-
Ignyta Announces Initiation Of STARTRK "Next Generation" Phase 1/1b Pediatric Clinical Trial Of Entrectinib
12/9/2015
-
Ignyta Receives Orphan Drug Designation In The European Union For Entrectinib For The Treatment Of Neuroblastoma
12/8/2015
-
Ignyta Appoints William Mccarthy As Chief Business Officer
12/7/2015
-
Ignyta To Present At Oppenheimer 26th Annual Healthcare Conference
12/2/2015
-
Ignyta Reports Granting Of Inducement Awards
12/2/2015
-
Ignyta And EORTC Announce Entrectinib Selected As First Investigational Cancer Agent To Be Included In EORTC SPECTA Precision Medicine Clinical Trial Program
11/30/2015